Freeline is a clinical-stage biotech focused on AAV-based gene therapy targeting the liver. The company’s lead program is in Haemophilia B, with plans to advance it into a pivotal trial. It is continuing a Phase 1/2 clinical program for Fabry disease and progressing pipeline programs for Gaucher disease and Haemophilia A. Freeline also intends to further develop its proprietary gene therapy platform using next-generation AAV technology. The company plans to expand its manufacturing capabilities to support these programs. Freeline is led by CEO Theresa Heggie and has operations in the UK, Germany and the US.

Total raised

$120M

Funding rounds

1

Latest round

Series C

Latest activity

Jul 2020